This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.
Written by the leading melanoma experts from the United States, Australia, and Europe, this new edition incorporates the clinical outcomes of more than 70,000 patients treated at major melanoma centers throughout the world and is the definitive and most authoritative textbook on melanoma used worldwide. Providing the most up-to-date and comprehensive information needed for the clinical management and scientific study of melanoma, Cutaneous Melanoma, 6th edition covers everything from precursors of melanoma to advanced stages of metastatic disease.
This book provides a comprehensive overview of brain metastases, from the molecular biology aspects to therapeutic management and perspectives. Due to the increasing incidence of these tumors and the urgent need to effectively control brain metastatic diseases in these patients, new therapeutic strategies have emerged in recent years. The volume discusses all these innovative approaches combined with new surgical techniques (fluorescence, functional mapping, integrated navigation), novel radiation therapy techniques (stereotactic radiosurgery) and new systemic treatment approaches such as targeted- and immunotherapy. These combination strategies represent a new therapeutic model in brain metastatic patients in which each medical practitioner (neurosurgeon, neurologist, medical oncologist, radiation oncologist) plays a pivotal role in defining the optimal treatment in a multidisciplinary approach. Written by recognized experts in the field, this book is a valuable tool for neurosurgeons, neuro-oncologists, neuroradiologists, medical oncologists, radiation oncologists, cognitive therapists, basic scientists and students working in the area of brain tumors.
Precision medicine is an emerging practice by which clinicians aim to deliver a personalized treatment program to affected patients based on information gained from their individual clinical and biological profiles. In the context of precise cancer immunotherapy, multi-omics, high-throughput sequencing, big data, and other approaches serve to screen new predictive factors for immunotherapy response and prognosis in cancer patients.
One of the current challenges and failures of immunotherapy is in part due to the complex tumor microenvironment (TME) that provides a formidable barrier to immune infiltration and function. The TME consists of various cell types (tumor cells, fibroblasts, endothelial cells, and immune cells), soluble signaling molecules (cytokines, growth factors, and chemokines), and extracellular matrix. On another note, metabolic disturbances in various TME components, such as hypoxia, acidosis, lactate accumulation, and nutrient deprivation, can play a critical role in the tumor progression. Furthermore, genetic and epigenetic dysfunctions are known to be part of the characteristics of cancer development. The immune cells could have a pro- or anti-tumor role in the TME, and their activity might vary in the context of different cancers. Both innate and adaptive immune cells interact with tumor cells through direct contact or through chemokines and cytokines signaling, shaping the tumor's activity and response to therapy.
Resistance to therapies, both targeted and systemic, and metastases to distant organs are the underlying causes of breast cancer-associated mortality. The second edition of Breast Cancer Metastasis and Drug Resistance brings together some of the leading experts to comprehensively understand breast cancer: the factors that make it lethal, and current research and clinical progress. This volume covers the following core topics: basic understanding of breast cancer (statistics, epidemiology, racial disparity and heterogeneity), metastasis and drug resistance (bone metastasis, trastuzumab resistance, tamoxifen resistance and novel therapeutic targets, including non-coding RNAs, inflammatory cytokines, cancer stem cells, ubiquitin ligases, tumor microenvironment and signaling pathways such as TRAIL, JAK-STAT and mTOR) and recent developments in the field (epigenetic regulation, microRNAs-mediated regulation, novel therapies and the clinically relevant 3D models). Experts also discuss the advances in laboratory research along with their translational and clinical implications with an overarching goal to improve the diagnosis and prognosis, particularly that of breast cancer patients with advanced disease.
In recent years, significant advancements have been made in the field of new drug development. With the advent of high-throughput sequencing technologies, the identification of new drug targets has become more efficient and precise. In addition, multi-omics approaches, including genomics, transcriptomics, proteomics, and metabolomics, have emerged as a powerful tool for understanding the complexity of diseases and identifying new therapeutic targets.